AbCellera Biologics (ABCL) - מזומן למניה

Liquid assets per share, which form this chart via GURU.Markets data, show that the value of 2.40 is the current metric. AbCellera Biologics (ABCL) bases its business on AI-driven antibody discovery and licenses from pharma behemoths. However, capital stability depends on the success of partners and R&D expenditures. The company's environmental policy is limited to the safe handling of chemicals and the energy efficiency of its laboratories.
פילוחים אנליטיים של חברת AbCellera Biologics

This indicator measures the amount of net liquid capital per share, allowing investors to determine the financial cushion and the risk of depleting reserves to cover operating expenses. For AbCellera Biologics (ABCL), whose competitive advantage is based on proprietary microfluidic screening, fluctuations in cash per share serve as a leading indicator of the company's ability to maintain its technological moat without external borrowing.